About Durata Therapeutics
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: DRTX
- CUSIP: 26658A10
Key Metrics:
- Previous Close: $0.00
- 50 Day Moving Average: $0
- 200 Day Moving Average: $24
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.64
- P/E Growth: 0
- Market Cap: $N/A
Additional Links:
Companies Related to Durata Therapeutics:
Earnings History for Durata Therapeutics (NASDAQ:DRTX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2014 | Q2 | ($0.73) | ($0.61) | | | View | N/A |  |
| 5/8/2014 | Q114 | ($0.64) | ($0.62) | | | View | N/A | |
| 3/14/2014 | Q413 | ($0.76) | ($0.59) | | | View | N/A | |
| 11/6/2013 | | ($0.60) | ($0.45) | | | View | N/A | |
| 8/7/2013 | Q2 2013 | ($0.52) | ($0.75) | | | View | N/A | |
| 5/9/2013 | 1Q13 | ($0.66) | ($0.86) | | | View | N/A | |
| 11/9/2012 | Q312 | ($1.00) | ($1.47) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Durata Therapeutics (NASDAQ:DRTX)Current Year EPS Consensus Estimate: $-2.97 EPS
Next Year EPS Consensus Estimate: $-1.37 EPS
Dividend History for Durata Therapeutics (NASDAQ:DRTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Durata Therapeutics (NASDAQ:DRTX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/12/2014 | John Patrick Shannon Jr | Insider | Buy | 3,000 | $13.72 | $41,160.00 | |
| 6/12/2014 | Paul R Edick | CEO | Buy | 3,000 | $15.23 | $45,690.00 | |
| 5/12/2014 | Schutter Richard De | Director | Buy | 15,000 | $15.57 | $233,550.00 | |
| 3/21/2014 | Aisling Capital Iii Lp | major shareholder | Sell | 100,649 | $15.74 | $1,584,215.26 | |
| 12/3/2013 | Lisa Giles | Director | Buy | 1,000 | $10.95 | $10,950.00 | |
| 5/20/2013 | Paul R Edick | CEO | Buy | 3,000 | $7.09 | $21,270.00 | |
| 8/14/2012 | Paul R Edick | CEO | Buy | 5,000 | $8.65 | $43,250.00 | |
(Data available from 1/1/2013 forward)
Latest Headlines for Durata Therapeutics (NASDAQ:DRTX)
Durata Therapeutics (NASDAQ:DRTX) Chart for Thursday, September, 29, 2016
